ODONATE THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits (form 8-K)

Item 2.05 Costs Associated with Exit or Disposal Activities

On March 19, 2021, Odonate Therapeutics, Inc. ("Odonate" or the "Company") committed to a plan of termination involving the termination of certain employees previously supporting the development of tesetaxel (the "Restructuring"). As previously announced on March 22, 2021, following feedback from the U.S. Food and Drug Administration ("FDA") in a pre-New Drug Application meeting, Odonate concluded that its clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company. Odonate estimates that the Restructuring will be substantially complete by June 30, 2021 and that costs incurred in connection with the Restructuring will be approximately $14 million.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits



Exhibit
  No.                                     Description

104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses